Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 2/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4627361 | 0.88 | PTGDR (0.58) | PTGDRPTGDR2LMNAMAPTF2 | |
| SCHEMBL2945278 | 0.87 | MAPT (0.70) | PTGDRPTGDR2LMNAMAPTF2 | |
| SCHEMBL23434716 | 0.86 | F2 (0.53) | PTGDRPTGDR2LMNAMAPTF2 | |
| SCHEMBL4628356 | 0.86 | GAA (0.54) | PTGDRPTGDR2MAPTF2SMN1; SMN2 | |
| SCHEMBL5007339 | 0.84 | HMGCR (0.56) | PTGDRPTGDR2LMNAMAPTF2 | |
| SCHEMBL11110347 | 0.83 | MAPT (0.74) | PTGDRPTGDR2MAPTTDP1TSHR | |
| SCHEMBL4626978 | 0.83 | MAPT (0.65) | PTGDRPTGDR2LMNAMAPTF2 | |
| SCHEMBL5007025 | 0.82 | GAA (0.62) | PTGDRPTGDR2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5004060 | 0.82 | PTGDR (0.73) | PTGDRPTGDR2LMNAMAPTTDP1 | |
| SCHEMBL4627039 | 0.82 | PTGDR2 (0.52) | PTGDRPTGDR2LMNAMAPTF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678826-B2 | Organic compounds for the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-03-16 | — | — | US | disclosed |
| EP-1891029-B1 | ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS | NOVARTIS AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-20080312322-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-12-18 | — | — | US | disclosed |
| US-20080200466-A1 | Organic Compounds For the Treatment of Inflammatory or Allergic Conditions | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | disclosed |
| EP-1891029-A1 | ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS | Novartis AG (CH) | 2008-02-27 | — | — | EP | disclosed |
| EP-1888505-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006125596-A1 | ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006125593-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312322-A1 | Organic Compounds | NR3C2, MRGPRX2, HRH2 | PTGDR 41/4885PTGDR2 49/4885LMNA 3262/4885 |
| US-20080200466-A1 | Organic Compounds For the Treatment of Inflammatory or Allergic Conditions | HRH2, MRGPRX2, HRH1 | PTGDR 36/4885PTGDR2 43/4885LMNA 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.